Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

60.52
Delayed Data
As of Feb 11
 -1.97 / -3.15%
Today’s Change
52.01
Today|||52-Week Range
134.26
-18.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$7.0B

Company Description

Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the following segments: Specialty Brands, Specialty Generics, and Nuclear Imaging. The Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals. The Specialty Generics segment engages in the production of specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Nuclear Imaging segment manufactures and markets radiopharmaceuticals. The company was founded on January 9, 2013 and is headquartered in Chesterfield, the United Kingdom.

Contact Information

Mallinckrodt Plc
Perth House, Millennium Way
Chesterfield Derbyshire S41 8ND
P:444246263051
Investor Relations:

Employees

Shareholders

Individual stakeholders8.03%
Other institutional62.22%
Mutual fund holders42.07%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Frank ScholzSenior Vice President-Global Operations
Matthew K. HarbaughChief Financial Officer & Senior Vice President
Steven RomanoChief Scientific Officer & Senior Vice President
Raymond J. FureyChief Compliance Officer & Senior Vice President